Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Earnings and Comprehensive Income

v3.22.2.2
Condensed Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Earnings and Comprehensive Income    
Net sales $ 269,655 $ 257,719
Cost of sales 90,060 86,722
Gross margin 179,595 170,997
Operating expenses:    
Selling, general and administrative 99,375 86,175
Research and development 23,903 21,600
Total operating expenses 123,278 107,775
Operating income 56,317 63,222
Other income (expense) 47,399 4,161
Earnings before income taxes 103,716 67,383
Income taxes (benefit) 13,982 (1,598)
Net earnings, including noncontrolling interest 89,734 68,981
Net earnings (loss) attributable to noncontrolling interest 179 (634)
Net earnings attributable to Bio-Techne 89,555 69,615
Other comprehensive income (loss):    
Foreign currency translation adjustments (21,457) (8,646)
Foreign currency translation reclassified to earnings with Eminence deconsolidation 119  
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 4,695 1,682
Other comprehensive income (loss) (16,643) (6,964)
Other comprehensive income (loss) attributable to noncontrolling interest (33) (39)
Other comprehensive income (loss) attributable to Bio-Techne (16,610) (6,925)
Comprehensive income attributable to Bio-Techne $ 72,945 $ 62,690
Earnings per share attributable to Bio-Techne:    
Basic $ 2.28 $ 1.78
Diluted $ 2.21 $ 1.69
Weighted average common shares outstanding:    
Basic 39,232 39,094
Diluted 40,543 41,158